These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30124844)

  • 1. Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting.
    Niward K; Davies Forsman L; Bruchfeld J; Chryssanthou E; Carlström O; Alomari T; Carlsson B; Pohanka A; Mansjö M; Jonsson Nordvall M; Johansson AG; Eliasson E; Werngren J; Paues J; Simonsson USH; Schön T
    J Antimicrob Chemother; 2018 Oct; 73(10):2838-2845. PubMed ID: 30124844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.
    Saktiawati AM; Sturkenboom MG; Stienstra Y; Subronto YW; Sumardi ; Kosterink JG; van der Werf TS; Alffenaar JW
    J Antimicrob Chemother; 2016 Mar; 71(3):703-10. PubMed ID: 26661397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
    Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
    Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.
    Verhagen LM; López D; Hermans PW; Warris A; de Groot R; García JF; de Waard JH; Aarnoutse RE
    Trop Med Int Health; 2012 Dec; 17(12):1449-56. PubMed ID: 23094704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol.
    Mlotha R; Waterhouse D; Dzinjalamala F; Ardrey A; Molyneux E; Davies GR; Ward S
    J Antimicrob Chemother; 2015; 70(6):1798-803. PubMed ID: 25759035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
    Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
    Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis.
    Shenje J; Ifeoma Adimora-Nweke F; Ross IL; Ntsekhe M; Wiesner L; Deffur A; McIlleron HM; Pasipanodya J; Gumbo T; Mayosi BM
    EBioMedicine; 2015 Nov; 2(11):1640-9. PubMed ID: 26870790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
    Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
    Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs.
    Baietto L; Calcagno A; Motta I; Baruffi K; Poretti V; Di Perri G; Bonora S; D'Avolio A
    J Antimicrob Chemother; 2015 Sep; 70(9):2572-5. PubMed ID: 26066583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children.
    Martial LC; Kerkhoff J; Martinez N; Rodríguez M; Coronel R; Molinas G; Roman M; Gomez R; Aguirre S; Jongedijk E; Huisman J; Touw DJ; Pérez D; Chaparro G; Gonzalez F; Aarnoutse RE; Alffenaar JW; Magis-Escurra C
    Int J Antimicrob Agents; 2018 Jul; 52(1):109-113. PubMed ID: 29751121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study.
    Prahl JB; Johansen IS; Cohen AS; Frimodt-Møller N; Andersen ÅB
    J Antimicrob Chemother; 2014 Oct; 69(10):2841-7. PubMed ID: 25140577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children.
    Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
    BMC Infect Dis; 2015 Mar; 15():126. PubMed ID: 25887748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous quantification of isoniazid, rifampicin, ethambutol and pyrazinamide by liquid chromatography/tandem mass spectrometry.
    Prahl JB; Lundqvist M; Bahl JM; Johansen IS; Andersen ÅB; Frimodt-Møller N; Cohen AS
    APMIS; 2016 Nov; 124(11):1004-1015. PubMed ID: 27546025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.
    Saleri N; Dembélé SM; Villani P; Carvalho AC; Cusato M; Bonkoungou V; Nacanabo R; Kouanda S; Comelli M; Regazzi M; Matteelli A
    J Antimicrob Chemother; 2012 Feb; 67(2):469-72. PubMed ID: 22028201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis.
    Ruslami R; Gafar F; Yunivita V; Parwati I; Ganiem AR; Aarnoutse RE; Wilffert B; Alffenaar JC; Nataprawira HM
    Arch Dis Child; 2022 Jan; 107(1):70-77. PubMed ID: 34183327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.
    Denti P; Wasmann RE; van Rie A; Winckler J; Bekker A; Rabie H; Hesseling AC; van der Laan LE; Gonzalez-Martinez C; Zar HJ; Davies G; Wiesner L; Svensson EM; McIlleron HM
    Clin Infect Dis; 2022 Aug; 75(1):141-151. PubMed ID: 34665866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?
    Trentalange A; Borgogno E; Motta I; Antonucci M; Pirriatore V; Costa C; Rossi G; Barco A; De Nicolò A; Piccioni P; D'Avolio A; Bonora S; Di Perri G; Calcagno A
    Int J Antimicrob Agents; 2021 Mar; 57(3):106297. PubMed ID: 33539932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study.
    Davies Forsman L; Niward K; Hu Y; Zheng R; Zheng X; Ke R; Cai W; Hong C; Li Y; Gao Y; Werngren J; Paues J; Kuhlin J; Simonsson USH; Eliasson E; Alffenaar JW; Mansjö M; Hoffner S; Xu B; Schön T; Bruchfeld J
    BMJ Open; 2018 Oct; 8(9):e023899. PubMed ID: 30287613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania.
    Denti P; Jeremiah K; Chigutsa E; Faurholt-Jepsen D; PrayGod G; Range N; Castel S; Wiesner L; Hagen CM; Christiansen M; Changalucha J; McIlleron H; Friis H; Andersen AB
    PLoS One; 2015; 10(10):e0141002. PubMed ID: 26501782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study.
    Hiruy H; Rogers Z; Mbowane C; Adamson J; Ngotho L; Karim F; Gumbo T; Bishai W; Jeena P
    J Antimicrob Chemother; 2015 Apr; 70(4):1115-23. PubMed ID: 25505005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.